Gwo Xi Stem Cell Applied Technology , Ltd Receivables

As of the most recent data (June 2026), 6704.TWO shows a receivables of $17M. That compares with $33M in the prior-year period — down 48.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6704.TWO's receivables is now $17M (was $33M) — a 48.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Gwo Xi Stem Cell Applied Technology , Ltd is outperforming or lagging.

Tracking 6704.TWO's receivables over time shows whether Gwo Xi Stem Cell Applied Technology , Ltd is scaling, shrinking, or reshaping that part of the business. The current reading is $17M That compares with $33M in the prior-year period — down 48.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Gwo Xi Stem Cell Applied Technology , Ltd's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $17M) with ownership activity and broader fundamentals.

Gwo Xi Stem Cell Applied Technology , Ltd's receivables is $17M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.